论文部分内容阅读
目的观察津力达口服液联合米格列醇治疗2型糖尿病(T_2DM)患者的临床效果。方法将234例T2DM初诊患者随机分为津力达组、米格列醇组和联合用药组,每组78例。治疗5个月后,比较3组患者治疗前后体质量、HbA1c、FBG、2h PBG、GLP-1、HOMA-IR等指标的水平变化。结果治疗5个月后,3组FBG、2h PBG、HbA1c、HOMA-IR、体质量显著下降,GLP-1联合用药组下降更为显著(P<0.05)。联合用药组的总不良反应发生率最低,米格列醇组不良反应发生率最高~[6],3组总不良反应发生率的差异有统计学意义(P<0.05)。结论津力达口服液联合米格列醇联合治疗T2DM,可有效控制血糖、减轻体质量,且低血糖风险小,值得推广应用。
Objective To observe the clinical effect of Jinlida oral solution combined with miglitol in the treatment of type 2 diabetes mellitus (T2DM). Methods 234 cases of newly diagnosed T2DM patients were randomly divided into Jin Lida group, miglitol group and combination group, 78 cases in each group. After 5 months of treatment, the changes of body weight, HbA1c, FBG, 2h PBG, GLP-1, HOMA-IR and other indexes were compared before and after treatment. Results After 5 months of treatment, the body mass of FBG, 2h PBG, HbA1c and HOMA-IR decreased significantly in GLP-1 group (P <0.05). The incidence of adverse reactions in the combination group was the lowest, and the incidence of adverse reactions was the highest in the miglitol group. [6] There was a statistically significant difference in the incidence of adverse reactions between the three groups (P <0.05). Conclusions The combination of Jinlida Oral Liquid and Miglitol in the treatment of T2DM can effectively control blood glucose, reduce body weight and reduce the risk of hypoglycemia, which is worth popularizing and applying.